The update of the AlsterResearch study on the Geratherm Group published on August 28, 2023 continues to give a buy recommendation with an unchanged price target of EUR 11.30. Despite sluggish sales in the first half of the year, gross margin improved significantly and reached its highest level in a decade. This and the company's overall performance as well as the long-term growth potential in the MedTec sector support the buy recommendation.

Via Research Hub, investors get free access to the update of Geratherm Medical's digital coverage.

Alternatively, you can find the update as a PDF file here.